A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
NCT02367456
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients must have previously untreated MDS, AML, or CMML according to the WHO 2016 classification.
- MDS patients must have Intermediate (>3 to 4.5 points), High Risk (>4.5 - 6) or Very High Risk (>6 points) disease according to the Revised International Prognostic Scoring System 2012 (IPSS-R).
- Clinical indication for treatment with azacitidine for MDS or AML.
- Patients with AML who are candidates for standard induction chemotherapy as first line
treatment.
- Patients with known active CNS leukemia.
- Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Cleveland, Ohio
- Salt Lake City, Utah
- Salt Lake City, Utah
- Calgary, Alberta
- Edmonton, Alberta
- Lille cedex,
- Lille cedex,
- Lille Cedex,
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- La Jolla, California
- La Jolla, California
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- Baltimore, Maryland
- Lebanon, New Hampshire
- Bronx, New York
- Bronx, New York
- Buffalo, New York
- Stony Brook, New York
- Stony Brook, New York
- Durham, North Carolina
- Durham, North Carolina
- Cleveland, Ohio
- Nashville, Tennessee
- Nashville, Tennessee
- Seattle, Washington
- Seattle, Washington
- Jette, Brussels
- Antwerpen,
- Leuven,
- Edmonton, Alberta
- Edmonton, Alberta
- Amiens cedex 01,
- Amiens,
- Angers,
- Angers,
- Paris Cedex 10,
- Paris Cedex 10,
- Paris Cedex 10,
- Pierre Benite Cedex,
- Pierre-Benite Cedex,
- Pierre-Benite,
- Tours Cedex 01,
- Berlin,
- Braunschweig,
- Liverpool,
- London,
- Newcastle upon Tyne,
- Oxford,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients | ||||||
Official Title ICMJE | AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA | ||||||
Brief Summary | This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE |
| ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Active, not recruiting | ||||||
Actual Enrollment ICMJE | 73 | ||||||
Original Estimated Enrollment ICMJE | 170 | ||||||
Estimated Study Completion Date ICMJE | January 31, 2021 | ||||||
Actual Primary Completion Date | January 29, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion criteria:
Exclusion criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Belgium, Canada, France, Germany, United Kingdom, United States | ||||||
Removed Location Countries | Taiwan | ||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT02367456 | ||||||
Other Study ID Numbers ICMJE | B1371012 2014-001345-24 ( EudraCT Number ) BRIGHT MDS&AML1012 ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | December 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |